Here's why the Cynata (ASX:CYP) share price is rising today

This biotechnology company has signed an agreement.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a company deal.

Shares in the biotechnology company are up 4.1%, trading at 50 cents at the time of writing.

Let's look at what might be impacting the Cynata share price today.

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

What did the company announce?

Cynata advised it was entering a manufacturing services agreement with the Wisconsin-based Fujifilm Cellular Dynamics (FCDI).

The agreement will enable FCDI to manufacture stem cell technology for Cynata to use in clinical trials and potential commercialisation. These stem cells are derived from induced pluripotent stem cells.

Cynata is an Australian-based company that is developing therapies to treat human disease using its Cymerus therapeutic stem cell technology. This includes its lead product CYP-001, which is at the planning stage for a phase 2 clinical trial.

FCDI is a global developer of human-induced pluripotent stem cell technologies.

What did management say?

Commenting on the agreement, Cynata chief operating officer Dr Killian Kelly said:

Ultimately, we foresee FCDI manufacturing product for our growing pipeline of clinical trials in high value indications and potentially for commercial use.

This provides a turn-key manufacturing solution that our future corporate partners may avail themselves of.

Importantly, FCDI has also confirmed a strong commitment to our relationship by agreeing to extending the voluntary escrow over their shares in Cynata.

Cynata initially flagged the deal to the market in September.

Now the deal is sealed, the companies will set up a manufacturing process for the Cymerus stem cell technology at the FCDI's US base.

Cynata share price snapshot

The Cynata share price has plummeted this year, down nearly 28% since January.

In contrast, the S&P/ASX 200 Index (ASX: XJO) is returning nearly 12% this year to date.

The company's shares have lifted more than 11% in the past five days alone.

The company has a market capitalisation of around $71 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Share Market News

Up 68% from a multi-year low. Are Telix shares a buy, sell or hold?

Telix shares crashed to just $8.63 per share in mid-February.

Read more »

Health professional working on his laptop.
Broker Notes

Are Orthocell shares a buy after crashing 7% yesterday?

These healthcare shares could be on discount right now.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares I think can beat the market

Healthcare trends like ageing populations and rising demand can create long-term opportunities.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up 2,000% in a year, why this ASX healthcare stock is in focus today

4DMedical shares rise as multiple updates land across key markets.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »